Contineum Therapeutics, Inc. (CTNM)

Every figure this model derived for CTNM, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2024-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 0 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 236,551,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 242,580,000 AssetsCurrent 2026-06-30
current liabilities 6,526,000 LiabilitiesCurrent 2026-06-30
equity 239,660,000 StockholdersEquity 2026-06-30
interest expense 0 InterestExpenseNonoperating 2024-12-31
revenue 0 RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31
sbc 0 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up CTNM on one particular measure came for.

RatioValue
current ratio37.17
current ratio reported37.17
dilution pct43.17
revenue growth-100.0
revenue growth per share-100.0

What to be careful about

What this model itself distrusts about CTNM's figures. Written by the derivation as it ran, not added afterwards.